Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accounts Payables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Accounts Payables for 16 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 7.12% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, down 7.12% year-over-year, with the annual reading at $30.0 million for FY2025, 7.12% down from the prior year.
  • Accounts Payables for Q4 2025 was $30.0 million at Myriad Genetics, down from $31.8 million in the prior quarter.
  • The five-year high for Accounts Payables was $39.8 million in Q2 2023, with the low at $15.7 million in Q3 2021.
  • Average Accounts Payables over 5 years is $29.3 million, with a median of $29.6 million recorded in 2021.
  • The sharpest move saw Accounts Payables plummeted 31.35% in 2021, then surged 88.54% in 2022.
  • Over 5 years, Accounts Payables stood at $29.6 million in 2021, then decreased by 2.7% to $28.8 million in 2022, then fell by 10.42% to $25.8 million in 2023, then increased by 25.19% to $32.3 million in 2024, then decreased by 7.12% to $30.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $30.0 million, $31.8 million, and $30.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.